Conference Coverage
Conference Coverage
MS disease activity returns in one-third after fingolimod withdrawal
BERLIN – Risk factors for higher disease activity include younger age at diagnosis, shorter disease duration, and stopping more than 2 months...
Conference Coverage
Anti-MOG antibodies associated with non-MS, monophasic demyelinating disease in young children
BERLIN – Age and anti-MOG antibody status may help to predict a non-MS diagnosis.
Conference Coverage
Demyelinating diseases, especially MS, disrupt normal brain development in children
Conference Coverage
Alemtuzumab switch linked to good MS outcomes
Conference Coverage
Vitamin D Levels at Onset Predict Subsequent Cognition in MS
BERLIN—Higher vitamin D levels at multiple sclerosis (MS) onset predict higher cognitive function 11 years later,...
Conference Coverage
To Escalate or Not to Escalate MS Therapy After Relapses?
BERLIN—Relapse-induced escalation to a highly effective disease-modifying therapy (DMT) is associated...
Conference Coverage
Low Spinal Cord Volume Associated With Increased MS Disability
BERLIN—Spinal cord volume deficits in patients with multiple sclerosis (MS) may explain clinical disability that appears...
Conference Coverage
Predicting Disability Following Clinically Isolated Syndrome
BERLIN—Smoking and low vitamin D levels are key modifiable prognostic factors that show a significant interaction with...
Conference Coverage
Long-Term Follow-Up of Ocrelizumab-Treated Patient With Relapsing MS
BERLIN—Switching from interferon beta-1a to ocrelizumab after two years at the start of the OPERA I and OPERA II open-...
Conference Coverage
Ongoing Neuronal Loss Is Greater in Secondary Progressive MS Than Primary Progressive MS
BERLIN—Levels of neurofilament light chain (NfL) indicate that patients with secondary progressive...
